Top

Obesity Surgery

Published in:

01-07-2018 | Original Contributions

The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients

Authors: W. Schijns, M. J. Deenen, E. O. Aarts, J. Homan, I. M. C. Janssen, F. J. Berends, K. A. H. Kaasjager

Published in: Obesity Surgery | Issue 7/2018

Abstract

Background

Morbidly obese patients are at increased risk to develop venous thromboembolism (VTE), especially after bariatric surgery. Adequate postoperative thrombosis prophylaxis is of utmost importance. It is assumed that morbidly obese patients need higher doses of low molecular weight heparin (LMWH) compared to normal-weight patients; however, current guidelines based on relative efficacy in obese populations are lacking.

Objectives

First, we will evaluate the relationship between body weight descriptors and anti-Xa activity prospectively. Second, we will determine the dose-linearity of LMWH in morbidly obese patients.

Setting

This study was performed in a general hospital specialized in bariatric surgery.

Methods

Patients were scheduled for a Roux-en-Y gastric bypass with a total bodyweight (TBW) of ≥ 140 kg. Patients (n = 50, 64% female) received a daily postoperative dose of 5700 IU of nadroparin for 4 weeks. Anti-Xa activity was determined 4 h after the last nadroparin administration. To determine the dose linearity, anti-Xa was determined following a preoperative dose of 2850 IU nadroparin in another 50 patients (52%).

Results

TBW of the complete group was 148.5 ± 12.6 kg. Mean anti-Xa activity following 5700 IU nadroparin was 0.19 ± 0.07 IU/mL. Of all patients, 32% had anti-Xa levels below the prophylactic range. Anti-Xa activity inversely correlated with TBW (correlation coefficient − 0.410) and lean body weight (LBW; correlation coefficient − 0.447); 67% of patients with a LBW ≥ 80 kg had insufficient anti-Xa activity concentrations. No VTE events occurred.

Conclusions

In morbidly obese patients, a postoperative dose of 5700 IU of nadroparin resulted in subprophylactic exposure in a significant proportion of patients. Especially in patients with LBW ≥ 80 kg, a higher dose may potentially be required to reach adequate prophylactic anti-Xa levels.

Afshin A et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. https://doi.org/10.1056/NEJMoa1614362.CrossRefPubMed

Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11(8):465–77. https://doi.org/10.1038/nrendo.2015.84.CrossRefPubMed

Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8(12):1711–21. https://doi.org/10.1586/erc.10.160.CrossRefPubMedPubMedCentral

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA : J Am Med Assoc. 2004;292(14):1724–37. https://doi.org/10.1001/jama.292.14.1724.CrossRef

Quebbemann B, Akhondzadeh M, Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg. 2005;15(9):1221–4. https://doi.org/10.1381/096089205774512528.CrossRefPubMed

Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24. https://doi.org/10.1381/096089202321144522.CrossRefPubMed

Escalante-Tattersfield T, Tucker O, Fajnwaks P, et al. Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. Surger Obes Related Dis : Off J Am Soc Bariatric Surger. 2008;4:126–30.CrossRef

Smith MD, Patterson E, Wahed AS, et al. Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg. 2011;21(11):1687–92. https://doi.org/10.1007/s11695-011-0497-8.CrossRefPubMedPubMedCentral

Becattini C, Agnelli G, Manina G, et al. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surger Obes Relat Dis : Off J Am Soc Bariatric Surger. 2012;8:108–15.CrossRef

10.

Birkmeyer NJ, Finks JF, Carlin AM, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Arch Surg. 2012;147(11):994–8. https://doi.org/10.1001/archsurg.2012.2298.CrossRefPubMed

11.

Finks JF, English WJ, Carlin AM, et al. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg. 2012;255(6):1100–4. https://doi.org/10.1097/SLA.0b013e31825659d4.CrossRefPubMed

12.

Stroh C, Birk D, Flade-Kuthe R, et al. Evidence of thromboembolism prophylaxis in bariatric surgery-results of a quality assurance trial in bariatric surgery in Germany from 2005 to 2007 and review of the literature. Obes Surg. 2009;19(7):928–36. https://doi.org/10.1007/s11695-009-9838-2.CrossRefPubMed

13.

Melinek J, Livingston E, Cortina G, et al. Autopsy findings following gastric bypass surgery for morbid obesity. Arch Pathol Lab Med. 2002;126(9):1091–5. https://doi.org/10.1043/0003-9985(2002)126<1091:AFFGBS>2.0.CO;2.CrossRefPubMed

14.

Overby DW, Kohn GP, Cahan MA, et al. Prevalence of thrombophilias in patients presenting for bariatric surgery. Obes Surg. 2009;19(9):1278–85. https://doi.org/10.1007/s11695-009-9906-7.CrossRefPubMed

15.

De Luca M, Angrisani L, Himpens J, et al. Indications for surgery for obesity and weight-related diseases: position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2016;26(8):1659–96. https://doi.org/10.1007/s11695-016-2271-4.CrossRefPubMedPubMedCentral

16.

Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep. 2015 Nov 23;7(4):5844. https://doi.org/10.4081/hr.2015.6027.CrossRefPubMedPubMedCentral

17.

Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064–83. https://doi.org/10.1345/aph.1L194.CrossRefPubMed

18.

Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001;11(6):670–6. https://doi.org/10.1381/09608920160558588.CrossRefPubMed

19.

Celik F, Huitema AD, Hooijberg JH, et al. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. Obes Surg. 2015;25(4):628–34. https://doi.org/10.1007/s11695-014-1435-3.CrossRefPubMed

20.

Mushtaq A, Vaughns JD, Ziesenitz VC, et al. Use of enoxaparin in obese adolescents during bariatric surgery—a pilot study. Obes Surg. 2015;25(10):1869–74. https://doi.org/10.1007/s11695-015-1630-x.CrossRefPubMed

21.

Diepstraten J, Hackeng CM, van Kralingen S, et al. Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients. Obes Surg. 2012;22:79122.CrossRef

22.

Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65. https://doi.org/10.2165/00003088-200544100-00004.CrossRefPubMed

23.

Heizmann M, Baerlocher GM, Steinmann F, et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106(4-5):179–81. https://doi.org/10.1016/S0049-3848(02)00188-3.CrossRefPubMed

24.

Barras MA, Duffull SB, Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther. 2008;83(6):882–8. https://doi.org/10.1038/sj.clpt.6100399.CrossRefPubMed

25.

Mahe I, Drouet L, Chassany O, et al. Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients? Pathophysiol Haemost Thromb. 2002;32(3):134–6. https://doi.org/10.1159/000065216.CrossRefPubMed

26.

Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26:31–8.CrossRef

27.

Diepstraten J, Janssen EJ, Hackeng CM, et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015;71(1):25–34. https://doi.org/10.1007/s00228-014-1760-4.CrossRefPubMed

28.

Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286–94. https://doi.org/10.1038/ijo.2011.100.CrossRef

29.

Gómez-Ambrosi J et al. Clinical usefulness of a new equation for estimating body fat. Diabetes Care. 2012;35(2):383–8. https://doi.org/10.2337/dc11-1334.CrossRefPubMedPubMedCentral

30.

Gómez-Ambrosi J, Andrada P, Valentí V, et al. Dissociation of body mass index, excess weight loss and body fat percentage trajectories after 3 years of gastric bypass: relationship with metabolic outcomes. Int J Obes. 2017;41(9):1379–87. https://doi.org/10.1038/ijo.2017.134.CrossRef

31.

Abou-Nukta F, Alkhoury F, Arroyo K, et al. Clinical pulmonary embolus after gastric bypass surgery. Surger Ob Relat Dis : Off J Am Soc Bariatric Surger. 2006;2(1):24–8; discussion 9. https://doi.org/10.1016/j.soard.2005.09.016.CrossRef

32.

Cotter SA, Cantrell W, Fisher B, et al. Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery. Obes Surg. 2005;15(9):1316–20. https://doi.org/10.1381/096089205774512690.CrossRefPubMed

33.

Winegar DA, Sherif B, Pate V, et al. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. Surger Obes Relat Dis : Off J Am Soc Bariatric Surger. 2011;7:181–8.CrossRef

34.

Agarwal R, Hecht TE, Lazo MC, et al. Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. Surger Obes Relat Dis : Off J Am Soc Bariatric Surger. 2010;6(2):213–20. https://doi.org/10.1016/j.soard.2009.11.018.CrossRef

35.

Homan J, Ruinemans-Koerts J, Aarts EO, et al. Management of vitamin K deficiency after biliopancreatic diversion wit or without duodenal switch. Surg Obes Relat Dis. 2016;12(2):338–44. https://doi.org/10.1016/j.soard.2015.09.021.CrossRefPubMed

36.

Venclauskas L, Maleckas A, Arcelus JI. European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the obese patient. Eur J Anaesthesiol. 2017; nov 6;

37.

K D, Kraaij L, Aarts EO, et al. Fast-track bariatric surgery improves perioperative care and logistics compared to conventional care. Obes Surg. 2015;25(1):28–35. https://doi.org/10.1007/s11695-014-1355-2.CrossRef

38.

Singh K, Podolsky ER, Um S, et al. Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2012;22(1):47–51. https://doi.org/10.1007/s11695-011-0397-y.CrossRefPubMed

39.

Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hospital Pharm. 2015;68(1):33–47.

Title: The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients
Authors: W. Schijns
M. J. Deenen
E. O. Aarts
J. Homan
I. M. C. Janssen
F. J. Berends
K. A. H. Kaasjager
Publication date: 01-07-2018
Publisher: Springer US
Published in: Obesity Surgery / Issue 7/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-018-3130-2

At a glance: The STEP trials

Springer Medicine

The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients

Abstract

Background

Objectives

Setting

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objectives

Setting

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Perioperative Outcomes of Laparoscopic and Robotic Revisional Bariatric Surgery in a Complex Patient Population

Comments on: “Oral Vitamin B12 Supplementation After Roux-en-Y Gastric Bypass: a Systematic Review”

Endoscopic Sleeve Gastroplasty (ESG) Is a Reproducible and Effective Endoscopic Bariatric Therapy Suitable for Widespread Clinical Adoption: a Large, International Multicenter Study

Binge Eating, Loss of Control over Eating, Emotional Eating, and Night Eating After Bariatric Surgery: Results from the Toronto Bari-PSYCH Cohort Study

The Effect of Pre-Surgery Information Online Lecture on Nutrition Knowledge and Anxiety Among Bariatric Surgery Candidates

ABSI (A Body Shape Index) and ARI (Anthropometric Risk Indicator) in Bariatric Surgery. First Application on a Bariatric Cohort and Possible Clinical Use